№ lp_2_1_19781
File format: docx Character count: 14022 File size: 3869 KB
This research article investigates IL-17 signaling in organoids derived from patients with primary sclerosing cholangitis, focusing on immune-related gene expression and sequencing analysis.
Year: 2023
Region / City: N/A
Subject: Primary Sclerosing Cholangitis, IL-17 Signaling
Document Type: Research Article
Organization / Institution: Mayo Clinic
Author: Ana Sofia Garcia Moreno, Maria Eugenia Guicciardi, Alexander Q. Wixom, Erik Jessen, Jingchun Yang, Sumera I. Ilyas, Jackie K. Bianchi, Filippo Pinto e Vairo, Konstantinos N. Lazaridis, Gregory J. Gores
Target Audience: Researchers, Healthcare professionals, Scientific community
Period of Validity: N/A
Date of Approval: N/A
Date of Changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
secukinumab mPBPK-TE-MBMA model based on IL-17 pharmacokinetics and target engagement
Year: 2013
Model type: mPBPK-TE-MBMA
Drug: secukinumab
Based on: 2nd generation mPBPK-TE model for IL-17 (Cao & Jusko, JPKPD, 2013)
Author: JLee
Data file: IL17_mPBPK_NM_v01_LN.csv
Subroutines: ADVAN6
Compartment description: ABS, serum, muscle, leaky, skin, lymph, total IL17A serum, total IL17A skin
Parameters: CL, FA, KA, L, LS, L1, L2, VP, V1, V2, VS, VL, kdegSK, kdegSE, kintSK, kintSE, BSsk, BSse, KD, sSK, s1, s2, sL
Error model: combined additive and proportional, log-transform for serum and skin PK
Simulation: 1234 replicates, NSUBPROBLEMS=1, ONLYSIM
Output tables: sdtab1128, patab1128, catab1001, cotab1001
Target audience: pharmacometricians, modelers
Scope: pharmacokinetic and target engagement predictions for secukinumab in serum and skin compartments
Obeticholic acid for the treatment of primary biliary cholangitis: cost-effectiveness of combination therapy with ursodeoxycholic acid and monotherapy
Year: 2023
Region / city: Australia
Subject: Pharmaceutical treatment for primary biliary cholangitis
Document type: Authority submission for PBS listing
Organization: Emerge Health Pty Ltd
Author: Emerge Health Pty Ltd
Target audience: Healthcare professionals, gastroenterologists, hepatologists, prescribers
Period of validity: Ongoing
Approval date: Not specified
Date of changes: Not specified
Topics: Sclerosing Il-17 Cholangitis